

Il potenziale della RLT in medicina

Numerose ricerche sono in corso per valutare l'eventuale impiego di radioligandi in alcune patologie, in ambito oncologico e non.

Ambiti in cui viene studiato l'utilizzo di radioligandi, come mezzi diagnostici o come farmaci.

PATOLOGIA	DESCRIZIONE
Linfoma e Linfoma non-Hodgkin [1,2]	Neoplasia che ha origine nei linfociti, cellule del sistema immunitario situate nei linfonodi, nel midollo osseo e in altre sedi [3]
Cancro al seno [4,5]	Neoplasia delle cellule della mammella, generalmente delle ghiandole lattifere o dei dotti [4]
Melanoma [6]	Una tipologia di cancro della pelle che coinvolge cellule chiamate melanociti [7]
Mieloma multiplo [8]	Cancro che si sviluppa nelle cellule plasmatiche del midollo osseo [9]
Cancro ai polmoni e tumore neuroendocrino dei polmoni [4]	Cancro ai polmoni o delle vie respiratorie [10]
Cancro al pancreas [11]	Tumore del pancreas (una ghiandola dell'apparato digerente) [12]
Aterosclerosi [13]	Accumulo di grassi e altro materiale all'interno delle arterie che tipicamente si manifesta con cardiopatia ischemica, ictus ischemico e malattie delle arterie periferiche [14]

Bibliografia

(1). Fahey F, Zukotynski K, Capala J, et al. 2014. Targeted radionuclide therapy: proceedings of a joint workshop hosted by the National Cancer Institute and the Society of Nuclear Medicine and Molecular Imaging. J Nucl Med 55(2): 337-48

(2). Lapa C, Hanscheid H, Kircher M, et al. 2019. Feasibility of CXCR4-Directed Radioligand Therapy in Advanced Diffuse Large B-Cell Lymphoma. J Nucl Med 60(1): 60-64

(3). Lymphoma Action. 2019. What is lymphoma? Available from: https://lymphoma-action.org.uk/aboutlymphoma/ what-lymphoma [Accessed 24/07/19]

(4). Salas Fragomeni RA, Amir T, Sheikhbahaei S, et al. 2018. Imaging of Nonprostate Cancers Using PSMATargeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms. J Nucl Med 59(6): 871-77

(5). Thundimadathil J. 2012. Cancer Treatment Using Peptides: Current Therapies and Future Prospects. J Amino Acids 2012: 13

(6). Rahbar K, Afshar-Oromieh A, Jadvar H, et al. 2018. PSMA Theranostics: Current Status and Future Directions. Mol Imaging 17: 1536012118776068

(7) . Cancer Research UK. 2018. What is melanoma? Available from: https://www.cancerresearchuk.org/ aboutcancer/ melanoma/about [Accessed 24/07/19]

(8). Schottelius M, Osl T, Poschenrieder A, et al. 2017. [(177) Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent. Theranostics 7(9): 2350-62

(9). Cancer Research UK. 2018. Myeloma. Available from: https://www.cancerresearchuk.org/about-cancer/ myeloma/about [Accessed 24/07/19]

(10). Cancer Research UK. 2017. About lung cancer. Available from: https://www.cancerresearchuk.org/aboutcancer/ lung-cancer/about [Accessed 24/07/19]

(11). Shah M, Da Silva R, Gravekamp C, et al. 2015. Targeted radionuclide therapies for pancreatic cancer. Cancer Gene Ther 22(8): 375-79

(12). National Health System UK. 2018. Overview: pancreatic cancer [online]. Available from: https://www.nhs.uk/ conditions/pancreatic-cancer/ [Accessed 02/10/19]

(13). Werner RA, Weich A, Kircher M, et al. 2018. The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go? Theranostics 8(22): 6088-100

(14). Herrington W, Lacey B, Sherliker P, et al. 2016. Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease. Circ Res 118(4): 535-46